Strategic Vision and Infarmed 2026 Priorities for Regulatory Reform

By João L. Carapinha

February 12, 2026

Infarmed 2026 Priorities Take Shape in Leadership Summit

Infarmed 2026 priorities crystallized during the Executive Board’s February 11, 2026, session with unit directors, led by President Rui Santos Ivo, Vice-President Raquel Ascenção, and Board Member Eduardo Costa. This followed the agency’s 33rd anniversary Advisory Council on January 15, amid statutory updates and a 416-strong workforce. Core themes: process simplification, digital transformation, and proportional regulation to safeguard public health while accelerating access to medicines and technologies.

Simplification and Digital Overhaul

Infarmed 2026 priorities spotlight process simplification, digitalization of procedures, and boosted organizational productivity. Examples include functional reorganization to streamline decisions and optimize resources, cutting response times with risk-based oversight. This internal agility serves citizens, professionals, and industry, fostering a knowledge-sharing culture to deliver maximum value—especially to the National Health Service—via collaborative unit innovation.

Advisory Council Momentum

The January 15 extraordinary Advisory Council introduced the new board to partners like the Health Directorate-General, health systems administration, professional orders, and patient groups. President Ivo reviewed 2025 wins and 2026 visions, joined by Secretary of State Ana Povo on SiNATS sustainability and Professor Arlindo Oliveira on transformative technologies. This stakeholder input shapes Infarmed 2026 priorities, including EU rules on medical devices, in vitro diagnostics, and medicine reserves.

Health Economics and Market Impact

Infarmed 2026 priorities may streamline SiNATS evaluations for faster market access, and reimbursement. Proportional, sustainable regulation eases pharma burdens, aligns with EU reforms for swift approvals, and bolsters Portugal’s EU health policy role. With workforce investments, it enhances post-market surveillance, tech assessment, leading to improved patient outcomes.

Reference url

Recent Posts

NICE Pembrolizumab Recommendation for Locally Advanced Head and Neck Cancer Treatment

By HEOR Staff Writer

March 25, 2026

NICE Pembrolizumab recommendation offers a major advance for adults with resectable locally advanced head and neck squamous cell carcinoma. This update provides an evidence-based overview of the final draft guidance issued by NICE recommending pembrolizumab, within its marketing authorisation, fo...
PEPFAR TB Impact: Averting Millions of Cases and Deaths Among HIV Patients

By HEOR Staff Writer

PEPFAR TB Impact has been profound, with the U.S. President’s Emergency Plan for AIDS Relief averting an estimated 11.0 million tuberculosis (TB) cases and 2.1 million TB-related deaths among persons with HIV between 2003 and 2024. The PEPFAR TB impact extends far beyond HIV, delivering substa...
Advancing Collaborative TB Innovation to Tackle Drug Resistance

By João L. Carapinha

March 24, 2026

Collaborative TB Innovation is essential to ending the world’s deadliest infectious disease. Tuberculosis (TB) still claims millions of lives each year, with rising drug resistance, climate-driven migration, and conflict severely undermining global progress. While the burden falls heaviest on low...